329results about "Inorganic active ingredients" patented technology

A method for treating cancer comprises the combined use of a therapeutically effective amount of elzovtinib or an elzovtinib analog, a derivative thereof, or a pharmaceutically acceptable salt, and a therapeutically effective amount of bortezomib, ibrutinib, or an analog, derivative, or pharmaceutically acceptable salt thereof. The composition and kit are included herein. The cancer may be refractory to bortezomib and / or ibrutinib.

The present invention discloses a preparation method and application of a class of silver nanocluster-embedded niobium polyacid crystalline materials with immunological activity, belonging to the technical field of pharmaceutical synthesis. The chemical formula of the silver nanocluster-embedded niobium polyacid crystalline materials with immunological activity is L x [Ag 30 Cl y (SeO3) (8‑y) (SiNb 18 O 54 )6]·zH2O; wherein, L is a counter cation or cationic group, 1 < x ≤ 70, 0 < y ≤ 8, 1 < z ≤ 150; the overall cluster structure of the silver nanocluster-embedded niobium polyacid crystalline materials with immunological activity is composed of the [Ag 30 Cl y (SeO3) (8‑y) (SiNb 18 O 54 )6] anion cluster and the corresponding counter cation or cationic group; this material has good water solubility and stability under physiological conditions, has high cytotoxicity and selectivity for tumor cells, especially CT26 colon cancer cells, can induce immunogenic death of tumor cells and activate the body's immune system, has little toxic and side effects on normal cells and organs, and has better biosafety than the traditional chemotherapeutic drug doxorubicin, and can be used as an anti-tumor immunotherapy drug in the biomedical field.

The present invention relates to a combination of a specific binding molecule that binds to human ANXA1 and a second active agent for use in the treatment of cancer. The second active agent includes thymidylate synthase inhibitors, nucleobase analogs, checkpoint inhibitors, proteasome inhibitors, taxanes, platinum-based chemotherapy agents, and nucleoside analogs. Suitable cancers for treatment include pancreatic cancer, colon cancer, breast cancer, lung cancer, myeloma, and mantle cell lymphoma. Also provided are related kits, products, and uses.

A method of treating cancer in a subject, the method comprising administering 8,8-difluoro-3-(2-(4-(4-methylpyridazin-3-yl)phenyl)-2-oxoethyl)-1,3,diazaspiro[4.5]decane-2,4-dione, a TRPM8 antagonist.

The present application belongs to the technical field of daily chemical preparation, and particularly relates to a gynecological gel for inhibiting bacteria, regulating microecological balance and tightening vagina and a preparation method thereof. The gynecological gel comprises the following raw materials in mass fractions: 0.5-1 parts of carbomer, 0.04-0.09 parts of sodium hydroxide, 1-3 parts of collagen, 0.01-0.06 parts of sodium hyaluronate, 0.5-1.5 parts of isomaltooligosaccharide, 2-5 parts of propylene glycol, 0.05-0.3 parts of hydroxybenzoic acid methyl ester, 0.02-0.15 parts of hydroxyphenyl ethyl ester, 0.1-1.5 parts of hydrogenated lecithin, 1-6 parts of 1,3-butanediol, 3-5 parts of glycerol, 0.5-1 part of xanthan gum and 70-90 parts of water. The present application uses buckwheat filtrate to prepare collagen, and the active ingredients in the buckwheat filtrate can penetrate the cell membrane of pathogenic bacteria to play an antibacterial role; the collagen can repair the vaginal mucosa barrier and reduce the adhesion and invasion of pathogenic bacteria; therefore, after being compounded with the raw materials such as carbomer, sodium hydroxide, sodium hyaluronate, isomaltooligosaccharide and propylene glycol, the multiple components can synergistically promote the synthesis and repair of collagen fibers and improve the elasticity of tissues.

Nutrient composition to support kidney health in older pets, characterized in that the nutrient composition comprises in mass percentages: 20-30% cellulose, 20-30% fat, 2-5% premixed amino acids, 2-7% prebiotics, 2-7% minerals, 1-5% antioxidants, 1-5% vitamin premix, 1-5% trace element premix, remainder as carrier.

The present invention relates to the use of a selected UV filter selected from the group consisting of octocrylene, ethylhexyl triazone, and t-butyl methoxydibenzoylmethane to protect skin bacteria of the genus Lactobacillus, such as Lactobacillus crispatus (L. crispatus), from UV radiation, preferably in the co-presence of Staphylococcus epidermidis, in order to promote the maintenance of the health of the skin microbiome after UV irradiation.

The application relates to the field of triple-negative breast cancer treatment and relates to synthesis of an acid-responsive amphiphilic liposome and application of the acid-responsive amphiphilic liposome in tumor treatment. A chemotherapeutic drug, a phospholipid, cholesterol and a polyethylene glycolized lipid are dissolved in an organic solvent chloroform, vacuum rotary evaporation is carried out under certain temperature and rotation rate, a water phase is added for hydration, a polypeptide nanogold cluster solution is added for ultrasonic treatment, then crushing, molecular sieve screening, dialysis and ultrafiltration are carried out to obtain a pH-sensitive liposome; in the preparation process, the phospholipid spontaneously forms a kind of biological membrane-like phospholipid bilayer membrane vesicle in water, and the chemotherapeutic drug and the nanogold cluster are wrapped in the vesicle. The pH-sensitive liposome can target the triple-negative breast cancer tumor site through pH response, can improve the solubility of the chemotherapeutic drug, can realize high-efficiency treatment effect of the drug at a low dose, can obviously reduce the toxic side effect of the chemotherapeutic drug, and can realize effective treatment of the triple-negative breast cancer.

This invention belongs to the field of traditional Chinese medicine adhesive bandage technology, specifically relating to a Shengji Yuhong Ointment, its preparation method, and a medicated film adhesive bandage. The Shengji Yuhong Ointment has a hydrogel structure, comprising raw materials, a gel matrix, and nano-zinc oxide or silver sulfadiazine nanoparticles. The raw materials include the following components by weight: 13-17 parts Angelica dahurica, 34-38 parts Glycyrrhiza uralensis, 58-62 parts Angelica sinensis root, 10-14 parts Dragon's Blood, 4-8 parts Lithospermum erythrorhizon, and 0.2-0.25 parts Musk-β-cyclodextrin inclusion complex powder or Musk nanoliposome powder. The matrix comprises the following components by weight: 245-255 parts sesame oil, 57-63 parts beeswax, 93-103 parts polymer material, 37-43 parts plasticizer, 3-8 parts penetration enhancer, and 0.8-1.2 parts preservative. The Shengji Yuhong Ointment of this invention is used in medicated film adhesive bandages, is convenient to use, and is particularly suitable for chronic, difficult-to-heal ulcers and acute wounds requiring accelerated healing.

The invention relates to compositions and methods for treating cancer in a patient comprising subcutaneously administering a PD-1 antagonist, e.g., an anti-PD-1 antibody (e.g. pembrolizumab), or antigen binding fragment thereof, with or without hyaluronidase every six weeks, in specific amounts to the patient. In specific embodiments, the amount of anti-PD-1 antibody, or antigen binding fragment thereof, is about 600 mg to about 1000 mg. In specific embodiments, the administration occurs about every three weeks, and the amount of anti-PD-1 antibody, or antigen binding fragment thereof, is about 300 mg to about 500 mg. In certain embodiments, the PD-1 antagonist is pembrolizumab, or an antigen binding fragment thereof. Also provided are compositions and kits formulated for subcutaneous administration comprising a particular dosage of an anti-PD-1 antibody, or antigen-binding fragment thereof, and uses thereof for treating cancer.

The present application relates to the technical field of disease detection, and more particularly to a method for diagnosing and treating early atherosclerotic plaques based on multifunctional nanomaterial CeOx-P@PM, which comprises the following steps: S1: assembling CeOx with a MMP2 specific probe to form a CeOx-P compound; and S2: coating the CeOx-P compound with a biomimetic platelet membrane as a carrier to assemble CeOx-P@PM nanoparticles. The method for diagnosing and treating early atherosclerotic plaques based on multifunctional nanomaterial CeOx-P@PM has the excellent characteristics of efficient ROS removal, high bioavailability, lesion targeting, and dual-mode precise imaging, and will provide great help for the diagnosis and treatment of early atherosclerotic plaques in clinical practice.

The application discloses a hydrotalcite nanocomposite, a preparation method and application thereof. The composite comprises a high-entropy hydrotalcite nanosheet matrix and platinum nanoclusters loaded on the matrix; and cations in the layer plate of the high-entropy hydrotalcite nanosheet matrix comprise cations of Cu, Mn, Co, Ni and Fe. A nanomedicine for treating tumors prepared by using the hydrotalcite nanocomposite has excellent catalytic ROS generation capacity.

The application discloses a kind of sustainable oxygen production sonodynamic therapy nanoparticles, including core-shell structure, the core of core-shell structure is located in shell inside, the core of core-shell structure is manganese oxide nanoparticle, the shell of core-shell structure is the high molecular polymer of carrying sound sensitizer, manganese dioxide nanoparticle is manganese dioxide nanoparticle, sound sensitizer is one of porphyrin and its derivatives, high molecular polymer is polylactic acid glycolic acid copolymer, this kind of sustainable oxygen production sonodynamic therapy nanoparticles by using high molecular polymer simultaneously carrying manganese dioxide nanoparticle and sound sensitizer to enhance SDT effect, high molecular polymer has good biocompatibility and drug controlled release performance, not only can reduce the toxicity of manganese dioxide to normal tissue, can also make it continuously controllable with tumor site excess H2O2 Reaction generates oxygen, reverses tumor hypoxic microenvironment while providing sufficient oxygen for SDT, under the action of ultrasound, generate a large amount of ROS to inhibit tumor.

The application provides a gold nanoparticle / cisplatin double crosslinking polyamino acid hydrogel and a preparation method and application thereof, which is composed of a chemotherapeutic drug cisplatin, gold nanoparticles, a polyamino acid block polymer containing a carboxyl functional group and a terminal thiol or selenol and a solvent. The polyamino acid block polymer comprises cysteamine or selenocysteamine and a polyamino acid segment. The hydrogel firstly constructs amino acid modified gold nanoparticles through a sulfur-gold or selenium-gold bond; further, a semi-solid hydrogel is obtained by using the coordination of the carboxyl functional group and the cisplatin drug. The gold nanoparticles and the cisplatin drug are not only crosslinking agents for gel formation, but also functional components for realizing the photo-thermal and chemotherapy of the hydrogel. The hydrogel sustained-release preparation has in-vivo chloride ion responsive drug release, can maintain a relatively long effective drug concentration in the body, and has considerable application prospect for long-acting local treatment of cancer.

This invention discloses a near-infrared light-exciteable composite nanosheet, its preparation method, and its applications, belonging to the field of biomedical technology. The method includes the following steps: mixing epigallocatechin gallate with a Ti3C2 nanosheet dispersion, ultrasonically reacting, adding silver salt, and continuing stirring in the dark; after the reaction is complete, washing and separating to obtain MXene-EGCG@Ag composite nanosheets. The composite nanosheets provided by this invention possess near-infrared light-exciteable properties and can be used to prepare medically acceptable dosage forms such as hydrogels for the treatment of periodontitis. The preparation method provided by this invention is simple, the raw materials are readily available, and it exhibits significant antibacterial and anti-inflammatory effects, enabling further widespread application.

The present invention relates to microencapsulation technology and specifically, nitrite salt microencapsulation and uses of microencapsulated nitrite in the manufacture of animal pest baits and toxic feed mixtures, especially baits and toxic feed mixtures to be used in humane methods for controlling pig and possum populations.

The present application provides a method for preparing a liposome composition. In the method, a containing step is provided, including: providing precursor liposomes wrapping a platinum drug precursor; and culturing the precursor liposomes in a salt solution to convert the platinum drug precursor into a platinum drug to obtain the liposome composition. The precursor liposomes are obtained by the following steps: hydrating the platinum drug to obtain the platinum drug precursor; and adding the platinum drug precursor to a lipid bilayer carrier to obtain the precursor liposomes. The liposome composition prepared by the method has better coating rate and stronger drug loading capacity.

The reduction in the sol-gel temperature of aqueous poloxamer surfactant compositions by the addition of hydrophobic vicinal diols is provided. Lowering of the sol-gel temperature and the gelling efficiency of water-soluble poloxamer block copolymers of polyethylene oxide-b- polypropylene oxide-b-polyethylene oxide has been markedly improved by the addition of small amounts of at least one hydrophobic vicinal diol, such as monoalkyl glycols, monoalkyl glycerols, or monoacyl glycerols. The decrease in the sol-gel temperature facilitates gel formation, and such gels exhibit greater residence time on a surface, particularly those with biological properties.

Provided is a method for treating cancer by administering to a subject in need thereof with a pharmaceutical composition including a benzenesulfonamide derivative and at least one other therapeutic agents in a different classification of anticancer agents.

This disclosure relates to methods, combinations, and uses for treating cervical cancer using anti-PD-L1 binding proteins or anti-PD-1 binding proteins and chemoradiotherapy.

The application provides a chlorogenic acid-europium nanoparticle and a preparation method and application thereof, and belongs to the technical fields of nanobiological materials and biological medicine. The preparation method of the chlorogenic acid-europium nanoparticle comprises the following steps: slowly mixing chlorogenic acid (CGA) and europium ions in a solvent, and self-assembling the CGA-Eu (Eu 3+ ) nanoparticles through intermolecular coordination, electrostatic interaction and hydrophobic effect. The CGA itself has good biomedical application potential, the addition of the europium ions causes coordination with the CGA to enhance the stability of the CGA and enrich the functions of the CGA. The CGA-Eu nanoparticles have good stability under physiological conditions, and can conditionally release the CGA and Eu 3+ ions under pathological microenvironments, and have multiple effects of antioxidation, anti-inflammation, antibiosis and promotion of angiogenesis, and excellent biocompatibility. The nanoparticles obtained through the method of the application solve the problem of instability of the chlorogenic acid under conventional environments, and have wide application prospects in the fields of biological medicine, health products and cosmetics.

The present invention aims to solve the problem of providing a novel combination therapy with excellent antitumor effects. The present invention provides an antitumor agent (excluding pembrolizumab as an active ingredient) which includes as an active ingredient, fobamintib or a pharmaceutically acceptable salt thereof, to be administered in combination with an immune checkpoint inhibitor (excluding a CD155 / TIGIT pathway antagonist) and at least one or more other antitumor agents to a cancer patient.

This invention belongs to the field of oral care technology and provides a bismuth microsphere oral care agent that eliminates halitosis and has anti-inflammatory and antibacterial properties. The agent comprises a bismuth complex, wherein the bismuth complex is a porous bismuth microsphere selected from Bi2O2CO3 and Bi2O2CO3@Bi2S3 heterojunctions. This oral care agent can rapidly respond to the high expression of H2S in periodontitis, eliminating halitosis, inhibiting inflammation, and regulating the periodontal microenvironment. Simultaneously, the (Bi2O2CO3) microspheres react with H2S to form Bi2O2CO3@Bi2S3 heterojunctions in situ, which can efficiently kill bacteria under light irradiation.

Methods and pharmaceutical compositions are provided, which make use of compounds disclosed herein, including (I). The methods and compositions are useful for producing local or regional anesthesia or analgesia in nerve tissue of a subject.

Polyhydric polymers may be converted to derivatives thereof by reaction with divinyl sulfone to provide vinyl sulfone substituted polymers, where the polymers may additionally be further derivatized, including crosslinked, and the crosslinked and non-crosslinked derivatives may be used in biomedical and other applications.

Multimodal cancer immunotherapy is a combination of cancer immunotherapies used to treat cancer in patients. T cell receptor diversity is used as a component of a method to treat cancer involving cancer therapy, including multimodal cancer immunotherapy.

This invention belongs to the field of daily chemical products technology, specifically relating to an antibacterial care liquid and its preparation method. It is processed from main ingredients and auxiliary ingredients. The auxiliary ingredients include the following components by weight percentage: purified water 89.30%, silver ions 3%, honeysuckle extract 1.2%, wild chrysanthemum extract 1.2%, purslane extract 1.2%, clover extract 1.0%, gentian root extract 1.0%, hyaluronic acid 0.5%, carbomer 0.8%, and triethanolamine 0.8%. The main ingredient is American cockroach extract, and the weight ratio of the main ingredient to the auxiliary ingredients is 3:100. The product of this invention has the effects of repairing skin cells and slowing down skin aging. It can solve the problems of dry and loose skin, and at the same time, it can resist acne and pimples, remove acne marks, lighten scars, and make the skin moist, shiny, and elastic. It also has a good repairing effect on various wounds such as ultraviolet rays and radiation burns, as well as bedsores and frostbite.

This invention discloses an ionizing radiation protective adhesive and its preparation method. The ionizing radiation protective adhesive comprises the following components by mass percentage: 0.5%~1.5% guar gum powder, 0.25%~1% borax, 5%~10% humectant, 0.1%~0.5% preservative, 1%~20% bismuth oxide, 1%~20% lanthanum oxide, 0%~0.1% fragrance, and the balance being deionized water. This invention's ionizing radiation protective adhesive achieves seamless skin coverage, can be shaped arbitrarily, and greatly increases comfort. It is highly suitable for radiation shielding of local organs or tissues during radiological diagnosis and treatment, especially for local shielding in X-ray diagnosis of infants and young children, demonstrating strong practicality.

Provided herein is Compound I or a pharmaceutically acceptable salt thereof for use in the prevention and / or treatment of a kidney condition or disease in a subject exposed to a nephrotoxin capable of inducing said kidney condition or disease.